Clinical Trial: A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07711184) titled 'A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer' on July 02.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Prostate Cancer

Intervention: DRUG: HRS-7525 tablets

HRS-7525 tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Published by HT Digital...